

Klebsiella pneumoniae, Strain MRSN 560539

Catalog No. NR-55571

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (*K. pneumoniae*), strain MRSN 560539 was isolated in 2018 from a human urine sample in North America as part of a global surveillance program. NR-55571 was deposited as an extensively drug-resistant strain (XDR), sensitive to amikacin, ceftazidime/avibactam, and tigecycline, intermediate to ceftazidime and tobramycin and resistant to ampicillin/sulbactam, aztreonam, cefepime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, ertapenem, gentamicin, imipenem, levofloxacin, meropenem, piperacillin/tazobactam, tetracycline and trimethoprim/sulfamethoxazole. NR-55571 was produced by inoculation of BEI Resources seed lot 70051113 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70080665

Manufacturing Date: 08JAN2026

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology Motility (wet mount) VITEK® MS (MALDI-TOF)	Gram-negative rods Report results Report results <i>K. pneumoniae</i>	Gram-negative rods Circular, convex, entire, smooth and cream (Figure 1) Non-motile <i>K. pneumoniae</i> (99.9%)
Antibiotic Susceptibility Profile^{1,2} Amikacin Ampicillin/sulbactam Aztreonam Cefepime Ceftazidime Ceftazidime/avibactam Ceftolozane/tazobactam Ceftriaxone Ciprofloxacin Ertapenem Gentamicin Imipenem Levofloxacin Meropenem Piperacillin/tazobactam Tetracycline Tigecycline Tobramycin Trimethoprim/sulfamethoxazole	Sensitive Resistant Resistant Sensitive Resistant Sensitive Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Resistant Intermediate Resistant	Sensitive (4 µg/mL) Resistant (≥ 32 µg/mL) Resistant (≥ 64 µg/mL) Intermediate (4 to 6 µg/mL) ³ Resistant (≥ 32 µg/mL) ⁴ Sensitive (0.5 µg/mL) Resistant (≥ 32 µg/mL) Resistant (≥ 64 µg/mL) Resistant (≥ 4 µg/mL) Resistant (≥ 8 µg/mL) Resistant (≥ 16 µg/mL) Resistant (≥ 16 µg/mL) Resistant (≥ 8 µg/mL) Resistant (≥ 16 µg/mL) Resistant (≥ 128 µg/mL) Resistant (≥ 16 µg/mL) Sensitive (1.5 µg/mL) ^{5,6} Intermediate (8 µg/mL) Resistant (≥ 320 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1450 base pairs)	≥ 99% sequence identity to <i>K. pneumoniae</i> , strain MRSN 560539 (GenBank: JAGYCO010000175.1)	99.7% sequence identity to <i>K. pneumoniae</i> , strain MRSN 560539 (GenBank: JAGYCO010000175.1) ⁷

Certificate of Analysis for NR-55571

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK[®]2 N812 and XN33 and ETEST[®].

³*K. pneumoniae*, strain MRSN 560539 was deposited as resistant to cefepime and was found to be sensitive for lot 70051112, but showed MICs of 4 µg/mL and 6 µg/mL (interpreted as intermediately resistant) for lot 70080665 during QC testing.

⁴*K. pneumoniae*, strain MRSN 560539 was deposited as intermediately resistant to ceftazidime but showed a MIC of 24 µg/mL (interpreted as resistant) for lot 70051112 during QC testing.

⁵MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁶The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁷Also consistent with other *Klebsiella* species

Figure 1: Colony Morphology



/Sonia Bjorum Brower/

Sonia Bjorum Brower

Technical Manager or designee, ATCC Federal Solutions

31 MAR 2026

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

